Celldex Therapeutics, Inc. (CLDX) stock
CLDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
$28.04−0.55 (-1.92%)
Close on Nov 17, 2026Market cap $2.20BP/E –Yield –
Celldex Therapeutics price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Celldex Therapeutics's price to book ratio was 3.3× on Nov 11, 2026, against 3.0× a year earlier. Over the last 5 years it ranged from 1.6× to 7.6×, with a median of 3.6×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 3.3× | +0.3 |
| 2025 | Dec 31, 2025 | 3.0× | +0.9 |
| 2024 | Dec 31, 2024 | 2.1× | −5.5 |
| 2023 | Dec 29, 2023 | 7.6× | +1.5 |
| 2022 | Dec 30, 2022 | 6.1× | +1.9 |
| 2021 | Dec 31, 2021 | 4.1× | +1.1 |
| 2020 | Dec 31, 2020 | 3.0× | +2.7 |
| 2019 | Dec 31, 2019 | 0.3× | +0.1 |
| 2018 | Dec 31, 2018 | 0.3× | −1.4 |
| 2017 | Dec 29, 2017 | 1.7× | +0.1 |
| 2016 | Dec 30, 2016 | 1.7× | −3.2 |
| 2015 | Dec 31, 2015 | 4.9× | −2.0 |
| 2014 | Dec 31, 2014 | 6.8× | −5.7 |
| 2013 | Dec 31, 2013 | 12.5× | +8.0 |
| 2012 | Dec 31, 2012 | 4.5× | +3.1 |
| 2011 | Dec 30, 2011 | 1.4× | +0.3 |
| 2010 | Dec 31, 2010 | 1.1× | – |
See a number that looks wrong?